SUPN Company Profile and Key Details

Q: Who are the executives of SUPN?

Dr. Jonathan RubinSenior Vice President of R&D and Chief Medical OfficerDr. Padmanabh P. BhattChief Scientific Officer & Senior Vice President of Intellectual PropertyMr. Timothy C. DecSenior Vice President & Chief Financial OfficerDr. Todd Horich M.B.A., Ph.D.Senior Vice President of Marketing & Market AccessMr. Taylor RaifordSenior Vice President of SalesMs. Tami T. MartinSenior Vice President of Regulatory AffairsMr. Kevin T. AndersonCompliance OfficerMr. Jack A. KhattarFounder, Pres, Chief Executive Officer, Sec. & DirectorDr. Bryan A. Roecklein Ph.D.Senior Vice President of Corporation Devel.Dr. Jonathan Rubin M.D., MBASenior Vice President of R&D and Chief Medical OfficerMr. Frank MottolaSenior Vice President of Quality, GMP Operations & Information TechnologyDr. Padmanabh P. Bhatt Ph.D.Chief Scientific Officer & Senior Vice President of Intellectual PropertyMs. Tami T. Martin Esq., R.N.Senior Vice President of Regulatory Affairs

NASDAQ : SUPN

Supernus Pharmaceuticals

$48.53

-1.4056-2.81%

Open: 12:08 PM

64.21

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Supernus Pharmaceuticals, Inc. (SUPN) stock declined over -2.81%, trading at $48.53 on NASDAQ, down from the previous close of $49.94. The stock opened at $49.83, fluctuating between $48.35 and $49.89 in the recent session.

Stock Snapshot

49.94

Prev. Close

2.79B

Market Cap

48.35

Day Low

-71.37

P/E Ratio

-0.68

EPS (TTM)

2.02

Cash Flow per Share

49.83

Open

57.58M

Number of Shares

49.89

Day High

87.16%

Free Float in %

16.86

Book Value

95.86K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 14, 2026	50.63	51.03	49.76	50.11	460.03K
Apr 13, 2026	50.64	50.80	49.65	49.95	347.31K
Apr 10, 2026	51.62	51.71	50.00	50.68	445.34K
Apr 09, 2026	51.43	52.32	51.00	51.50	498.76K
Apr 08, 2026	51.97	52.37	50.71	51.61	618.49K
Apr 07, 2026	50.20	51.06	49.57	50.96	873.93K
Apr 06, 2026	50.23	51.24	49.82	50.54	438.42K
Apr 02, 2026	50.49	51.37	50.08	50.48	472.49K
Apr 01, 2026	51.37	52.69	51.32	51.44	535.28K
Mar 31, 2026	49.81	51.94	49.65	51.69	395.3K
Mar 30, 2026	49.88	50.07	48.85	49.35	560.68K
Mar 27, 2026	50.36	51.13	49.00	49.52	547.75K
Mar 25, 2026	50.01	50.78	49.81	50.06	425.56K
Mar 24, 2026	48.80	49.87	48.24	49.38	548.68K
Mar 23, 2026	48.86	49.36	47.75	49.25	831.15K
Mar 20, 2026	49.09	49.29	46.83	47.76	1.19M
Mar 19, 2026	49.07	49.87	48.57	48.84	559.2K
Mar 18, 2026	50.48	50.48	48.91	49.29	575.95K
Mar 17, 2026	50.13	51.15	49.40	50.82	549.29K
Mar 16, 2026	50.01	51.00	47.71	50.21	517.22K

Contact Details

Rockville, MD 20850

United States

https://www.supernus.com 301 838 2500

About Company

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Stock Peers

ITCI

Intra-Cellular Therapies, Inc.$131.87 NBIX

4.49+3.55%

Neurocrine Biosciences, Inc.$130.81 LNTH

1.07+1.31%

Lantheus Holdings, Inc.$82.74 ANIP

-0.02-0.03%

ANI Pharmaceuticals, Inc.$78.29 PAHC

-0.56-0.94%

Phibro Animal Health Corporation$59.02 HROW

0.8+2.16%

Harrow Health, Inc.$37.90 COLL

0.02+0.06%

Collegium Pharmaceutical, Inc.$35.64 INDV

1.37+4.34%

Indivior Pharmaceuticals Inc$32.97 PETQ

-0.01-0.03%

PetIQ, Inc.$30.98 RGC

-2.13-6.61%

Regencell Bioscience Holdings Limited$30.11

Company Overview

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) closed at $48.53 USD, losing -$1.41 (-2.81%) from the previous close of $49.94. The stock is currently mid-range between its 52-week high and low $29.16 and $59.68. With a market capitalization of about $2.79 billion, Supernus Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.73). Key stats such as the average daily volume over the past year has been around 720.23 thousand shares, volume is running light vs its 52-week average. Headquartered in Rockville, MD, Supernus Pharmaceuticals, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Jack A. Khattar, the company employs approximately 674 people and listed since May 01, 2012. Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 9.41%, SMA50 10.51%, SMA200 28.05%). The stock’s 14-day RSI is 68.34 (firm momentum), while the ATR of 2.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.59% below its high and over 91.19% above its low. Average 10-day trading volume of 526.04 thousand shares is below the 3-month average of 711.55 thousand, indicating normal recent market interest.

Valuation Metrics

Supernus Pharmaceuticals, Inc. trades at a P/E ratio of -74.5, slightly below the S&P 500 average, with a price-to-sales ratio of 4.01 and a price-to-book ratio of 2.71 suggesting the stock is closer to book value. The P/FCF stands at 62.7, also above market averages.

Dividend & Fair Value

Supernus Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $78.30. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 17.09% annually over the next five years. The latest quarter delivered EPS of -$0.80. The next quarter is forecast at $0.46. Next year's EPS is expected at $44.23. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 2 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $65.00 to $40.00. The high target offers 29.71% upside. The low target suggests -20.18% downside. The mean target is $56.29. This offers 12.33% upside. Supernus Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by -197.34%. The prior quarter beat by 93.62%. Over the last six quarters, Apple has recorded several small beats. These include -3.41% in August 06, 2024.

Shareholding & Insider Activity

Supernus Pharmaceuticals, Inc. has 56.07 million shares outstanding. The public float is 48.89 million shares, elevated short interest at 11.94% of float. This equals 4.70 million shares. The short ratio is 4.59 days. Institutional investors hold 108.92% of the float. Insiders own 4.26%. Khattar Jack A. holds 958.10 thousand shares, NEWHALL CHARLES W III has 104.64 thousand shares and Martin Tami Tillotson has 85.66 thousand shares. Over the past six months, insider transactions show net selling. They sold 92.33 thousand shares across 13 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Supernus Pharmaceuticals generated $607.52M in revenue, or $10.94 per share. Gross margin was 72.24%, operating margin 2.21%, and net profit margin 0.22%. Returns are modest, with ROA at 0.09% and ROE at 0.14%.
On valuation metrics, Supernus Pharmaceuticals trades at a P/E of -74.50, P/S of 4.01 and P/B of 2.71. The current ratio is 1.90 and quick ratio is 1.66. Operationally, the company’s inventory turnover is 1.26 and cash conversion cycle is 375.28 days. Debt-to-equity is 0.04, supported by a cash flow-to-debt ratio of 1.16.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Supernus Pharmaceuticals posted revenue of $607.52M, down slightly from $667.24M in the prior quarter. Gross profit was $438.88M (margin 72.24%). Operating income was $13.40M (margin 2.2%). Net income was$1.32M (EPS $0.02).
The company ended the quarter with $254.87M in cash and short-term investments, a total debt of $41.53M, and net debt of - $33.53M. Total assets were $1.41B, with equity of $921.52M. Financials further reflected stability, with operating cash flow of $111.09M, free cash flow of $110.53M, and capital expenditures of - $551.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Supernus Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.24%, with price expected at $50.73 by April 28, 2026, within a range of $48.86 to $52.74 3-Month Outlook: Projected fall of -8.38%, reaching $45.91 by July 13, 2026, with a range of $42.77 to $48.82. 1-Year Outlook: Projected gain of 13.21%, with price at $56.73 by April 14, 2027, within a range of $54.42 to $58.87.

Key Takeaways

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares are flat 0.24% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Supernus Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -74.5. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $45.88, suggesting -8.44% downside. Our AI forecast model points to short-term strength (1.24% over two weeks), a medium-term fall (-8.38% over three months), and a longer-term gain (13.21% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Supernus Pharmaceuticals, Inc. (SUPN) stock price?

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) stock price is $48.53 in the last trading session. During the trading session, SUPN stock reached the peak price of $49.89 while $48.35 was the lowest point it dropped to. The percentage change in SUPN stock occurred in the recent session was -2.81% while the dollar amount for the price change in SUPN stock was - $1.41.

SUPN's industry and sector of operation?

The NASDAQ listed SUPN is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Supernus Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SUPN?

Dr. Jonathan Rubin
Senior Vice President of R&D and Chief Medical Officer
Dr. Padmanabh P. Bhatt
Chief Scientific Officer & Senior Vice President of Intellectual Property
Mr. Timothy C. Dec
Senior Vice President & Chief Financial Officer
Dr. Todd Horich M.B.A., Ph.D.
Senior Vice President of Marketing & Market Access
Mr. Taylor Raiford
Senior Vice President of Sales
Ms. Tami T. Martin
Senior Vice President of Regulatory Affairs
Mr. Kevin T. Anderson
Compliance Officer
Mr. Jack A. Khattar
Founder, Pres, Chief Executive Officer, Sec. & Director
Dr. Bryan A. Roecklein Ph.D.
Senior Vice President of Corporation Devel.
Dr. Jonathan Rubin M.D., MBA
Senior Vice President of R&D and Chief Medical Officer
Mr. Frank Mottola
Senior Vice President of Quality, GMP Operations & Information Technology
Dr. Padmanabh P. Bhatt Ph.D.
Chief Scientific Officer & Senior Vice President of Intellectual Property
Ms. Tami T. Martin Esq., R.N.
Senior Vice President of Regulatory Affairs

How SUPN did perform over past 52-week?

SUPN's closing price is 71.84% higher than its 52-week low of $29.16 where as its distance from 52-week high of $59.68 is -16.04%.

How many employees does SUPN have?

Number of SUPN employees currently stands at 674.

Link for SUPN official website?

Official Website of SUPN is: https://www.supernus.com

How do I contact SUPN?

SUPN could be contacted at phone 301 838 2500 and can also be accessed through its website. SUPN operates from 9715 Key West Avenue, Rockville, MD 20850, United States.

How many shares of SUPN are traded daily?

SUPN stock volume for the day was 95.86K shares. The average number of SUPN shares traded daily for last 3 months was 720.23K.

What is the market cap of SUPN currently?

The market value of SUPN currently stands at $2.79B with its latest stock price at $48.53 and 57.58M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	674
Beta	0.72
Sales or Revenue	$607.52M
5Y Sales Change%	0.416%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

SUPN Company Profile and Key Details

Supernus Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Valuation Metrics

Price Forecast & Outlook

Key Takeaways